Cargando…

Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

BACKGROUND: Histone deacetylases (HDACs) have been associated with malignant tumor development and progression in humans. HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, −2, −4 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giaginis, Constantinos, Damaskos, Christos, Koutsounas, Ioannis, Zizi-Serbetzoglou, Adamantia, Tsoukalas, Nicolaos, Patsouris, Efstratios, Kouraklis, Gregorios, Theocharis, Stamatios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621854/ https://www.ncbi.nlm.nih.gov/pubmed/26502922 http://dx.doi.org/10.1186/s12876-015-0379-y

Ejemplares similares

Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival
por: Giaginis, Constantinos, et al.
Publicado: (2014)

Heat Shock Protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival
por: Giaginis, Constantinos, et al.
Publicado: (2009)

Increased RCAS1 Expression Is Associated with Advanced Histopathological Stage and Poor Prognosis in Patients with Gastric Adenocarcinoma
por: Giaginis, Constantinos, et al.
Publicado: (2013)

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
por: Psilopatis, Iason, et al.
Publicado: (2021)

Correlation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) and Retinoid X Receptor-α (RXR-α) expression with clinical risk factors in patients with advanced carotid atherosclerosis
por: Giaginis, Constantinos, et al.
Publicado: (2011)

Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors
por: Pouloudi, Despoina, et al.
Publicado: (2021)

Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients’ Survival
por: Levidou, Georgia, et al.
Publicado: (2021)

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
por: Palamaris, Kostas, et al.
Publicado: (2022)

Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
por: Garmpis, Nikolaos, et al.
Publicado: (2022)

Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors
por: Palamaris, Kostas, et al.
Publicado: (2023)

Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions
por: Lakiotaki, Eleftheria, et al.
Publicado: (2015)

Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
por: Goutas, Dimitrios, et al.
Publicado: (2021)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2022)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer
por: Xu, Xiaoxin S, et al.
Publicado: (2011)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

Role of histone deacetylase inhibitors in diabetic cardiomyopathy in experimental models (Review)
por: Garmpi, Anna, et al.
Publicado: (2022)

CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2
por: Boucheron, Nicole, et al.
Publicado: (2014)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
por: Wagner, Julia M., et al.
Publicado: (2010)

The Histone Deacetylase HDAC4 Regulates Long-Term Memory in Drosophila
por: Fitzsimons, Helen L., et al.
Publicado: (2013)

Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer
por: Cui, Zhuhong, et al.
Publicado: (2018)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
por: Wang, Yuren, et al.
Publicado: (2017)

Regulating the Regulators: The Role of Histone Deacetylase 1 (HDAC1) in Erythropoiesis
por: Kim, Min Young, et al.
Publicado: (2020)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options
por: Manou, Maria, et al.
Publicado: (2023)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
por: Urias, Beatriz Silva, et al.
Publicado: (2022)

Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo
por: Kelly, R. D. W., et al.
Publicado: (2018)

HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment
por: Papatheofani, Vasiliki, et al.
Publicado: (2021)

Expression of acetylated histones H3 and H4 and histone deacetylase enzymes HDAC1, HDAC2 and HDAC6 in simple mammary carcinomas of female dogs
por: Senhorello, Igor Luiz Salardani, et al.
Publicado: (2023)

The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells
por: Urwanisch, Laura, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j5ld3mdlolb2ll77ebb93fa8js